Comparative Pharmacology
Head-to-head clinical analysis: SYNJARDY XR versus XULTOPHY 100 3 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNJARDY XR versus XULTOPHY 100 3 6.
SYNJARDY XR vs XULTOPHY 100/3.6
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synjardy XR is a combination of empagliflozin, an SGLT2 inhibitor that reduces renal glucose reabsorption, and metformin, an AMPK activator that decreases hepatic glucose production and improves insulin sensitivity.
Xultophy 100/3.6 is a combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist). Insulin degludec binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production. Liraglutide activates GLP-1 receptors, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
Initial dose: 5 mg empagliflozin/500 mg metformin extended-release orally twice daily with meals. Titrate based on glycemic control and tolerability up to maximum 25 mg empagliflozin/1000 mg metformin XR twice daily.
Subcutaneous injection once daily, starting at 10 units (10 units insulin degludec and 3.6 mcg liraglutide). Titrate by 2 units every 3-4 days based on fasting plasma glucose to a maximum of 50 units daily.
None Documented
None Documented
Empagliflozin: Terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: Terminal half-life ~6.2 hours (plasma); elimination half-life prolonged in renal impairment (up to 17.6 hours in patients with reduced GFR).
Insulin degludec: ~25 hours (range 22-28 hours); liraglutide: ~13 hours. The ultra-long half-life of insulin degludec allows once-daily dosing with flat activity profile.
Empagliflozin: Approximately 54% excreted unchanged in urine, 41% in feces (metabolites). Metformin: ~90% excreted unchanged in urine via tubular secretion and glomerular filtration; renal clearance ~510 mL/min.
Renal: insulin degludec and liraglutide are cleared primarily via degradation, with less than 2% excreted unchanged renally. Fecal: negligible.
Category C
Category C
Antidiabetic
Antidiabetic